A Phase 1 human clinical trial using hESCs was approved by FDA in 2009 popularly referred to as the Geron trial. Though the initial results of the trial were promising, it was left midway due to financial constraints. 18 Further, there have been safety concerns and challenges in the use of hESCs. Most of the hESCs being used have been exposed to xeno-products during isolation and propagation. As a result, these could carry a risk of xenogenetic pathogen cross transfer and other unknown substances capable of eliciting a detrimental immune response in transplanted hosts. The cells used in Geron trial also contained animal components such as B27 supplement or Matrigel.
Introduction
Human embryonic stem cells (hESCs) are self-renewing cells with a potential to differentiate into all types of human cells. 1 These cells have the potential for cell replacement and regeneration therapies for human diseases. hESCs were derived and characterized as early as 1982 from fresh or frozen cleavage stage donated human embryos produced by in vitro fertilization (IVF). 2 The viable cell lines were obtained from the inner cell mass or blastocyst. hESCs have also been derived and established from single blastomeres of the 4 or 8 celled embryo and 16 celled morula. [3] [4] [5] [6] [7] Since then, a plethora of research has been done using hESCs for various diseases like diabetes, liver disorders, auto-immune disorders, immune disorders, Parkinson's disease, Alzheimer's disease, age related macular degeneration and spinal cord injury. [8] [9] [10] [11] [12] [13] [14] Despite huge potential in curing chronic and terminal conditions, hESCs have not been used extensively in humans. This is largely due to the ethical consideration in procuring the hESC lines and also lack of knowledge for the use of hESCs. Further, hESC cell lines have shown chromosomal and genomic instability, with acquisition of loss of heterozygosity or copy-number variation in cancer-related genes. 15, 16 hESCs have also been associated with teratoma formation and fear of being immunologically rejected. 17 These challenges have hindered the use of hESCs to their full potential.
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Methods
Study Characteristics
This was a single cohort study to establish safety and efficacy of hESCs in terminally ill patients carried out at Nutech Mediworld, New Delhi. The study included the patients enrolled in different cohorts in 2002 and 2004. The first patient was admitted on 31 March 2002. The patients were included in the study after an informed consent. The consent process involved a detailed discussion about the hESC therapy with the patient accompanied by a family member or caretaker. All the patients were informed that the treatment protocol being followed is being developed and is not yet finalized. The patients were also made aware of the adverse events (AEs) that might occur due to hESC therapy. All the information regarding the patients, a detailed report of the therapy and outcomes on patients and commencement of therapy was given to Government of India. We followed the guidelines of biomedical research (year 2000) on human participants in India. 20 During the entire procedure, an anesthetist was present and safety and sterile measures for hESC transplantation were followed. The transplantation was done at a medical centre registered under Delhi Government.
Study Population
Patients suffering from various degenerative diseases including Parkinson's disease, spinal cord injuries, autosomal recessive disorders, motor sensory neuropathy with diplopia (vasculitis), mild diffuse cerebral atrophy, Huntington's chorea, liver metastasis, diabetic foot (amputation), diabetes mellitus, psoriasis, chronic renal failure secondary to lupus nephritis, systemic lupus erythematosus (SLE), Duchene's muscular dystrophy (DMD), cirrhosis, mental retardation with microcephaly, hypothalamic astrocytoma, post traumatic paraplegia, developmental delay, colitis, and acute cauda equine lesions received hESC therapy. Patients who were pregnant, lactating or confirmed to have received other forms of cell therapy within 12 months of the treatment were not included.
Cell Culture and Differentiation
hESCs were obtained from a single, spare, expendable, pre implantation stage fertilized ovum taken during natural in vitro fertilization (IVF) process with due consent. These cells are cultured and maintained as per our proprietary in-house technology in a GMP, GLP and GTP certified laboratory. The technology has now been patented (United States Granted Patent No US 8592, 208, 52). The detailed cell culture and differentiation techniques have been elaborated elsewhere. The cell lines have been cultured and maintained in animal products free conditions making them suitable for clinical cell therapy. A detailed composition of hESCs used in this study their derivatives, methods of use, and methods of preparation are available at http://patentscope.wipo.int/ search/en/WO2007141657).
A quality check was performed on the stored cell batches which included integrity, viability and microbial contamination. The cells were characterized and the transplanted cells were octamer-binding transcription factor 4 positive (OCT4 +ve); Stage-specific embryonic antigen 3 (SSEA3)+ve; NANOG +ve; SOX +ve; β actin +ve; β-human chorionic gonadotropin (β -HCG) +ve; alkaline phosphatase +ve; CD 34 +ve; Nestin +ve, GATA +ve; GAF +ve; NeuN +ve; and transfer gene (TRA) -ve. The characterization was done by fluorescence-activated cell sorting (FACS), polymerase chain reaction (PCR) and immunoflourescence (Nikkon Ellipse E200; BD Acuri, Biorad T 100 Thermal cycle) (Unpublished data, Paper under submission).
Study Procedure
The cells were transplanted through simple injections of hESC suspension under skin in the abdominal wall. A single injection contained 0.25 mL of hESC suspension (1 mL contains approximately 4 million cells).
Variables for Analysis
Safety Evaluation: The safety of hESC therapy was evaluated by assessing the AEs experienced by patients during the study. Any disabling symptom/sign that a patient suffered after the test dose was given was considered as an AE. The medical staff of Nutech Mediworld carefully examined the patients for any AEs keeping the ones related to hESCs in mind. These AEs included teratomas, antigen-antibody reactions and any other sign and symptom.
Efficacy Evaluation: The efficacy of hESC therapy was evaluated based on the improvement seen in the patients.
Data Analysis
No formal sample size was calculated for this study. Each case was assessed at admission or soon after admission to determine the pre-therapy status of the case. The safety analyses were performed on safety population (patients who took at least one dose of hESC). The efficacy was assessed based on the improvement seen in the patients. No statistical assumptions were made.
Results
Study Patients
In the year 2002, 4 patients started hESC therapy. The first injection of hESCs was given to a patient with cortico basal degeneration on 31 Mar 2002. In year 2003, six patients received hESC therapy. The details of these patients are shown in Table 1 . In the year 2004, 23 patients with different chronic or terminal conditions were administered hESC therapy. Of these 23 patients, 4 had SCI, 3 had Duchenne's muscular dystrophy, 2 had Huntington's Chorea, 1 had Parkinsonism, 1 had Psoriasis, 1 had cauda equina Syndrome, 1 had postastrocytoma brain damage with seizures and slow learning, 1 had systemic lupus erythematosus, 1 had developmental delay, 1 had dementia, 1 had Alzheimer's disease, 1 had alcoholic cirrhosis with portal hypertension, 1 had genetic disorder, 2 had post cerebro vascular accident (CVA), 1 had uncontrolled diabetes with right bundle branch block and 1 had multiple sclerosis.
Safety Evaluation
No serious AEs were reported during the study period. All the AEs were mild in nature and resolved within one or two days with symptomatic medication and rest. Pain and fever were the most common AEs observed during the study. Headache, mild pain in the abdomen, swelling of legs (edema), urinary tract infection (UTI), rash/erythema, pain at the lower back and limbs and body ache were the other common AEs observed during the study. Table 2 lists the AEs observed during the study period in our patients.
Efficacy Evaluation
The improvement in patients after the therapy is tabulated in Table 1 . Since this was not an efficacy study, we did not analyze 
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A AN NN NA AL LS S RES ARTICLE the efficacy data. However, we observed an improvement in specific parameters of all our patients during the study, Figure 1 . discussion hESCs have an inexhaustible potential to differentiate into different cell types making it a promising treatment option for many debilitating conditions. The first embryonic stem cells (ESCs) were derived from mice (mESCs) in the year 1981. 21 Thomson et al isolated the first hESCs derived from human blastocysts about two decades later. 2 Since then, studies have been ongoing to prove and utilize their therapeutic prowess. However, ethical considerations and safety regarding the use of hESCs have limited their widespread use.
Adult stem cells are ethically preferable but are lineage restricted and have a limited capacity of self-renewal, which is the essence of stem cell therapy. Further, the sources of human adult stem cells are limited and their isolation is a challenge and can be painful for the patient. Human induced pluripotent stem cells (iPSCs) derived from various somatic cells have generated a tremendous interest for their use in stem cell therapy and regenerative medicine. Though effective, iPSCs might cause genetic and epigenetic abnormalities that could take place during reprogramming or maintenance of iPSCs in subsequent cell culture. [22] [23] [24] The potential tumorigenicity and immunogenicity associated with iPSC-based cell therapy is of significant concern. [25] [26] [27] hESCs have an edge over adult stem cells and iPSCs as they display low immunogenicity and could be transplanted with minimal immunosuppression. [28] [29] Maintaining an undifferentiated stem cell state during large scale expansion (without spontaneous differentiation) is an uphill task that has hindered their widespread use. Another issue is direct or indirect exposure of cells to animal products while culturing that results in high risk of graft rejection and transfer of non-human pathogens to the recipient. Some researchers have been able to maintain and expand undifferentiated hESC on human feeder layers or feeder free matrices but the scale of expansion is low. 30, 31 Further, majority of the methods adopted for culturing hESCs could result in genetically unstable and aberrant cell lines. 32 Most of the hESCs used till date have been derived from inner cell mass (ICM) of blastocyst embryos before implantation. 
A AN NN NA AL LS S RES ARTICLE and culturing under particular conditions. This blastocyst is the 256-celled stage of human embryo that has developed from 2-celled, 4-celled, 8-celled stage and so on. The blastocyst continues to mature for an additional 24 hours and is ready to implant into the uterine wall. These preimplantation embryos are able to develop in synthetic culture media for several days and are highly adaptable. 35 Though pluripotency at this blastocyst stage has been studied extensively using various marker and characterization studies, there is a paucity of studies about cells at the initial stages of developments. In our study, we used hESCs that are generated in a culture from a one-time harvest made at the pre-blastocyst stage. Expendable, fertilized ovum was taken after a natural IVF cycle and informed consent was sought from the donor. The cell line thus developed is created from a single fertilized ovum 24-48 hr after fertilization when the conceptus is assumed to have reached the 4-16 cell stage. All the media used in the culture are free from animal contaminants and cells of animal origin. The composition of the present therapy is simple to prepare and cost effective. The ready to inject form is easily transportable, scalable and has a good shelf life. The evidence for the use of hESCs at our facility has been gathered over a number of years and was accepted as a written evidence to House of Lords, Regenerative Medicine, Science and Technology Committee report. 36 Stem cells have a unique functioning when transplanted. Previous studies suggest that various factors like chemokines, cytokines, and other growth factors released from the site of injury attractant the transplanted stem cells. These cells then migrate to the damage site due to up regulation of selectins and integrins on their surface, a process called "homing". [37] [38] [39] [40] After homing at the injured site, the stem cells help in "rescue" and "replacement" of the injured cells. We assume that the hESC in our study also acted in a similar way and reached the site of injury after transplantation. Once there, a trigger of factors led to their differentiation into the cell type of injured area and helped in recovery/regeneration.
When we tested our cell line in patients with differing chronic and life threatening conditions, we got promising results. The studies from 2002 to 2004 were done to establish the safety of these cell lines and develop a protocol for using the therapy. During these years, we did not observe any serious AE associated with the use of out cell line. Fever and generalized pain were the most common AEs that we observed after hESC injections. All the AEs were mild in nature and were observed majorly not due to hESC transplant per se, but were a direct consequence of the patient's illness and were part of the normal course of the disease. Though not the primary objective, efficacy of the hESC therapy was promising and we observed a continued benefit in our patients. Our cell line is a mixture of "neuronal" and "non-neuronal" cells. The non-neuronal cell lines include progenitor cells for hematopoietic stem cells progenitors, insulin producing stem cells, mesenchymal stem cell, epithelial stem cells, hepatocyte stem cell, and cardiac stem cells. The presence of these two directed cell lines makes them appropriate for usage in a wide variety of conditions. In this study, our patients suffered from different non-curable diseases like cortico-basal degeneration, SCI, cerebral palsy, corticovisual impairment, Parkinsonism etc. but the hESCs seemed to have beneficial effects for all of them. Further, all our patients had come to us after trying all the conventional treatments without any improvement. Now, the protocol of using hESC therapy in patients with different chronic and life threatening conditions has been fully developed and we have used our therapy in over 1300 patients over last decade. Till date, we have not observed any serious AE in our patients. As largely concerned about the usage of hESCs, we have not observed any teratoma formation in our patients till date. We did not give steroids or immunosuppressant to our patients. None of the patient had an immune response. Our staff is trained to observe any antigenic/anaphylactic response in the patients.
In conclusion, our hESC cell line is safe for use in humans afflicted with incurable conditions. We did not observe any serious AE in our patients. No teratoma formation or immune response was observed. We also observed clinical benefits of these cell lines in all our patients. Future, prospective controlled studies to substantiate the present study are ongoing.
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4.
Any usage of cells in human subjects has to be conducted as a trial which involves an animal study before permission is given to conduct in humans but this stage has to be allowed by regulations and until date regulations are slow to react. Big companies like Geron etc (which has been mentioned in the article) have gone into a trial after a rigorous study by FDA. At the time (in year 2000), when we started hESC research in our facility; stem cell research in India was in its infancy. We recruited our first patient in 2002 and established safety of hESC therapy from 2002 to 2004. Till this time also, no guidelines were available for stem cell research.
The only guidelines that were available are from Indian Council of Medical Research (ICMR) on their website and are issued every year (available at http://icmr.nic.in/ethical_guidelines.pdf).Few points to consider here are: For every patient that we recruited, we informed and reported to regulatory authority. Detailed reports of outcome of every patient after the therapy were also submitted .
The institute has IEC/ICSCRT and has applied for registration to NAC-SC etc. The guidelines state that tissues for transplantation can be obtained from embryos after spontaneous or induced abortion. Further, informed consent should be obtained from the mother whose embryo is sought. This was done.
Lastly, an IEC is in place since 2003. The Institutional Committee for Stem Cell Research and Therapy (ICSCRT) sent annual report to the National Apex Body (ICMR).
5.
For any research, there has to be a quantitative value of improvement. The 2 tables that were shown here were of qualitative nature. They were of no significant value. We agree that we have not quantified the improvement. Please note that, all the patients who visited us had chronic level of injury. The patients came after undergoing several other treatments that did not show any benefits. However, after undergoing hESC therapy, all patients suffering from different medical conditions showed improvement in their health. These are medical observations by qualified doctors.
The objective of this was only to assess the safety of hESC therapy. Hence, we did not assess the quantitative improvement.
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6.
The informed consent is written very very badly and there are glaring mistakes and misinterpretations. This has to be changed by the author. The consent is very old and we agree that it is not up to the mark. We have changed our consent form. Further, we are also taking video consents for our patients.
7.
The pictures are sent separately and have to be a part of the paper. This needs to be looked at by the author. We would modify the paper and send the pictures embedded in the paper.
8.
As this involves a contentious issue, the committees have been very careful to grant permission to such a study unless it goes through a full blown trial such as the Phase I through IV. This involves millions of dollars and not just going to the patient with no backup data. The backup data is present. All the data from these patients and others also was validated by independent CROs. These included Moody's International, QSA and GVK biosciences.
9. This study is not under the scope of DCGI in India so it cannot be a drug and ICMR does not take responsibility for these cells on human subjects. We agree to this. However, we would like to bring it to your notice that we started this study, we made a project proposal and approached DST. DST guided us to ICMR and then we submitted our project to them. Since then, we have been submitting all our reports to ICMR. Recently, in Dec 2014, we presented our work and submitted report to the expert committee meeting.
10. This is under the restrictive category of research. Restrictive and prohibited categories are banned in India. Restrictive research with minimal manipulation is allowed under 2012 guidelines (Section 7.1, page 14).
Disclaimer: This is a pure experimental study and the study does not come under the purview of accepted Medical Treatment for the patient as stipulated by regulatory agencies world wide who control the use of Stem Cells on Human subjects.
